1) Irinotecan(CPT-11)
伊立替康(CPT-11)
2) Irinotecan
伊立替康
1.
Advancement in the Synthesis and Clinical Application of the New Anticancer Drug Irinotecan;
抗肿瘤新药伊立替康的合成和应用进展
2.
The adverse reactions and management of irinotecan;
盐酸伊立替康的不良反应及其预防处理
3.
Short-term effects of irinotecan plus capecitabine as first-line treatment for advanced colorectal carcinoma;
伊立替康联合卡培他滨—线治疗晚期结直肠癌的近期疗效
3) Irinotecan hydrochloride
盐酸伊立替康
1.
Preparation and quality evaluation of irinotecan hydrochloride lyophilized liposomes
盐酸伊立替康脂质体冻干粉针的制备及其质量评价
2.
Preparation of irinotecan hydrochloride containing liposomes by ammonium sulfate gradient method and its release in vitro
硫酸铵梯度法制备盐酸伊立替康脂质体及体外释放的研究
3.
METHODS:Irinotecan hydrochloride liposome was prepared by ammonium sulfate gradient method.
目的:制备盐酸伊立替康脂质体并考察其体外释药特性。
4) irinotecan/therapeutic use
伊立替康/治疗应用
5) Irinotecan hydrochloride trihydrate
盐酸伊立替康三水合物
6) Irinotecan
伊利替康
1.
Irinotecan versus Oxaplatin in Combination with 5-FU/LV for Advanced Colorectal Cancer:A Systematic Review;
奥沙利铂联合5-FU/LV与伊利替康联合5-FU/LV比较治疗晚期结直肠癌的系统评价
补充资料：伊立替康
分子式：C33H38N4O6
分子量：586.69
CAS号：97682-44-5
性质：暂无
制备方法：暂无
用途：抗癌药。
分子量：586.69
CAS号：97682-44-5
性质：暂无
制备方法：暂无
用途：抗癌药。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条